(Total Views: 570)
Posted On: 03/22/2021 5:10:31 PM
Post# of 148908
CD16 was good to go, but they decided to get more specific and split into:
CD16 for patients <65, endpoint alive with no respiratory failure
CD17 >= 65, Intravenous initial dose, followed by two subcutaneous
both of these should dispel any doubt about results, delay's worth it imo
CD16 for patients <65, endpoint alive with no respiratory failure
CD17 >= 65, Intravenous initial dose, followed by two subcutaneous
both of these should dispel any doubt about results, delay's worth it imo
(8)
(0)Scroll down for more posts ▼
